Growth and development in preterm infants receiving fluoroquinolones.
Growth and development were followed in 7 preterm newborn infants who received fluoroquinolones in the neonatal period. Quinolones were used as a "life saving" therapy in cases of sepsis caused by bacterial agents sensitive only to these drugs. Two other groups of neonates matched for gender, birth weight and gestational age served as controls. Although the quinolone group had more severe illness, no statistically significant differences were observed in growth and development between the groups. No osteoarticular problems or joint deformities were observed in the quinolone group. Therefore, quinolones could be a therapeutic option for newborns with sepsis caused by multiply resistant organisms.
Martell
M
M
Latin American Center for Perinatology and Human Development, Montevideo, Uruguay.
de Ben
S
S
Weinberger
M
M
Beltrami
G
G
D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D001827:Body Height; D001835:Body Weight; D002657:Child Development / Q000187:drug effects*; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D006257:Head / Q000254:growth & development; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000254:growth & development*; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D008137:Longitudinal Studies; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D024841:Fluoroquinolones